ESMO 2017
ESMO 2017: Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice
September 13, 2017
ESMO 2017: Outcomes of patients with metastatic urothelial carcinoma with exclusive bone metastases: Focus on a special patient population
September 13, 2017
ESMO 2017: Kidney Cancer Poster Discussion – Invited Discussant
September 13, 2017
ESMO 2017: Avelumab treatment of metastatic urothelial carcinoma in the phase 1b JAVELIN Solid Tumor study: Updated analysis with ≥6 months of follow-up in all patients
September 13, 2017
ESMO 2017: Immunotherapy for Urothelial Cancer – Longer Follow-up and Subgroup Analyses: Invited Discussant
September 13, 2017
ESMO 2017: 14 years of progress in mCRPC – New avenues for immunotherapy and precision medicine: Invited Discussant
September 13, 2017
ESMO 2017: Prostate Cancer Poster Discussion: Invited Discussant
September 13, 2017
ESMO 2017: Urothelial Carcinoma Poster Discussion – Invited Discussant
September 13, 2017
ESMO 2017: Biological assessment of viable germ cell tumor in patients with seminoma and non-seminoma using miR371
September 13, 2017
ESMO 2017: Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma: Real world data from an Italian Expanded Access Program
September 13, 2017
ESMO 2017: Association between biopsychosocial distress and overall survival in patients with metastatic renal cell carcinoma
September 13, 2017